AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15670888
Drug: dTpa formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dTpa formulation with 0.3 mg aluminium
Trial: 15670888
Drug: dTpa formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dTpa formulation with 0.133 mg aluminium
Trial: 15670888
Drug: dTpa formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dTpa formulations with varying aluminium content
Trial: 28148500
Drug: Calcium with
RxNorm normalized name: Calcium with Vit D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium with vitamin D (1000 mg elemental Ca with 400 IU vitamin D3/d)
Trial: 9790450
Drug: Leukocyte interferon-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leukocyte interferon-alpha (LE-IFN-alpha) administered at a dose of 3 MU three times a week for six months (group A)
Trial: 9790450
Drug: Leukocyte interferon-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leukocyte interferon-alpha (LE-IFN-alpha) administered at a dose of 3 MU three times a week for twelve months (group B)
Trial: 15919695
Drug: Daily haemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily haemodialysis (DHD)
Trial: 8959286
Drug: Lorazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (2 mg IV push)
Trial: 25165161
Drug: Inactivated Influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated Influenza Vaccine (IIV)
Trial: 24633761
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during the first week of treatment.
Trial: 2192634
Drug: Efamol (evening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efamol (evening primrose oil) at a dose of 6 capsules daily
Trial: 2192634
Drug: Placebo (equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (equivalent dose of capsules)
Trial: 27709248
Drug: Two-injection digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-injection digital nerve block technique
Trial: 27709248
Drug: Single-injection digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection digital nerve block technique
Trial: 26670307
Drug: Colestilan (6-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestilan (6-15 g/day)
Trial: 7898095
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists
Trial: 11055468
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy with beta-blockers and diuretics
Trial: 8735863
Drug: Bronchodilators only
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilators only
Trial: 8153921
Drug: Bronchodilator tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator tests
Trial: 8153921
Drug: Bronchodilator response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bronchodilator response at the start of the study
Trial: 2873740
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers or clofibrate
Trial: 2873740
Drug: Probucol or
RxNorm normalized name: probucol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol or diuretics
Trial: 25864104
Drug: Ombrabulin plus
RxNorm normalized name: Ombrabulin
DrugBank: Ombrabulin (DB12882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ombrabulin plus cisplatin (25 mg/m2 plus 75 mg/m2 every 3 weeks)
Trial: 25864104
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus cisplatin (placebo plus 75 mg/m2 every 3 weeks)
Trial: 22658401
Drug: Almorexant (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almorexant (200 mg p.o.) with ethanol (0.6 g/L i.v. ethanol clamp for 5 h)
Trial: 22658401
Drug: Ethanol (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.6 g/L i.v. ethanol clamp for 5 h)
Trial: 19143675
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (K‐Y Jelly; Personal Products Inc., Raritan, NJ, USA)
Trial: 16397514
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil monotherapy
Trial: 16397514
Drug: Olmesartan medoxomil/HCTZ
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil/HCTZ double therapy
Trial: 16397514
Drug: Olmesartan medoxomil/HCTZ/Amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil/HCTZ/Amlodipine besylate triple therapy
Trial: 15106393
Drug: Nine-week group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nine-week group cognitive-behavioral therapy (CBT) intervention
Trial: 11358906
Drug: Interferon therapy
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon therapy (leucocytic interferon alfa, escalating schedule for 12 months)
Trial: 8181261
Drug: Nicotinamide (NCT)
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinamide (NCT) 25 mg kg‐1 day‐1
Trial: 8181261
Drug: Nicotinamide (NCT)
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinamide (NCT) 25 mg kg‐1 day‐1 + Cyclosporin (CyA) 5 mg kg‐1 day‐1
Trial: 12365468
Drug: Insulin only
RxNorm normalized name: Isophane insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin only (Control)
Trial: 3063587
Drug: Magnesium aspartate
RxNorm normalized name: Magnesium aspartate
DrugBank: Magnesium aspartate hydrochloride (DB16619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium aspartate (Mg 5‐Longoral) at a daily dose of 15 mmol
Trial: 16771960
Drug: Meropenem 500
RxNorm normalized name: meropenem 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 500 mg t.i.d. started at admission (group A)
Trial: 16771960
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (group B) - antibiotics started after demonstration of necrosis
Trial: 15273638
Drug: One-visit endodontic
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-visit endodontic treatment (including a 10‐min intraappointment dressing with 5% iodine‐potassium‐iodide)
Trial: 11453892
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg twice daily for 7 days)
Trial: 7912102
Drug: Pindolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (5 mg twice daily for 7 days)
Trial: 7912102
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg twice daily for 7 days)
Trial: 3579530
Drug: Integrated behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated behavioral therapy
Trial: 3579530
Drug: Traditional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional physical therapy (Bobath therapeutic exercises)
Trial: 9443427
Drug: Intravenous conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous conjugated estrogens (1.25 mg)
Trial: 10336572
Drug: Diltiazem 200
RxNorm normalized name: diltiazem hydrochloride 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 200 mg
Trial: 7690093
Drug: Diltiazem 300
RxNorm normalized name: diltiazem 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 300 mg
Trial: 11600740
Drug: Rheumatoid Arthritis
RxNorm normalized name: Rheumatoid arthritis nuclear antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire applied to patients with increasing difficulty in performing activities of daily living
Trial: 31443789
Drug: Voretigene neparvovec-rzyl
RxNorm normalized name: Voretigene Neparvovec-rzyl
DrugBank: Voretigene neparvovec (DB13932)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voretigene neparvovec-rzyl (VN) gene therapy, 1.5×10^11 vector genomes (vg) per eye, subretinal injection.
Trial: 30261008
Drug: Metformin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2 × 850 mg) for 7 days
Trial: 14513291
Drug: [123I]IPT administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [123I]IPT administration
Trial: 6896646
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of allopurinol (1H‐pyrazolo‐(3,4‐d) pyrimidin‐4‐ol) administered orally for 7 days
Trial: 20002779
Drug: 0.7 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 mg/day rhGH for 40 weeks
Trial: 16223204
Drug: DHEP lecithin
RxNorm normalized name: Lecithin
DrugBank: Lecithin (DB15834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEP lecithin gel (1.3%) applied 5 g t.i.d. for 10 days
Trial: 16223204
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied 5 g t.i.d. for 10 days
Trial: 10447627
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (600 cGy single dose between 2nd and 4th postoperative day)
Trial: 10447627
Drug: Indomethacin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (2 x 50 mg per day from 1st to 42nd postoperative day)
Trial: 2233916
Drug: Methylprednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (40 mg) every 6 hours for 7 days
Trial: 20179669
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment alone
Trial: 535845
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (diet + d-triiodothyronine)
Trial: 27093128
Drug: Mentalization-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-based treatment (MBT) adherence and competence
Trial: 12411657
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (background risk)
Trial: 25630353
Drug: Continued seizures,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued seizures, adverse events, and failure of initial treatment
Trial: 25630353
Drug: Treatment withdrawal
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment withdrawal
Trial: 23520669
Drug: Chemoradiation plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation plus topical application of honey
Trial: 12563568
Drug: Telmisartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (40 mg)
Trial: 10546920
Drug: Valsartan (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (80 mg)
Trial: 27824680
Drug: Candesartan (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (8 mg)
Trial: 9204594
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg for 28 days, amoxicillin 3 x 500 mg for 7 days, metronidazole 3 x 500 mg for 5 days
Trial: 9204594
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg for 28 days, ACA (amoxicillin 500 mg plus clavulanic acid 125 mg) 3 x 625 mg for 7 days, metronidazole 3 x 500 mg for 5 days
Trial: 8128836
Drug: Physostigmine (intravenous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (intravenous, 2 hours)
Trial: 8128836
Drug: Tetrahydroaminoacridine (THA,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrahydroaminoacridine (THA, mean dose 104 ± 20 mg/day, 6 weeks)
Trial: 1941390
Drug: Ibuprofen (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (both dosages)
Trial: 29045584
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (OT)
Trial: 16239807
Drug: Shock wave
RxNorm normalized name: ELECTRODE GEL,H-WAVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shock wave therapy
Trial: 27814307
Drug: Placebo shock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo shock wave therapy
Trial: 21928913
Drug: Zolpidem extended-release
RxNorm normalized name: zolpidem Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem extended-release (12.5 mg)
Trial: 15117561
Drug: Honey solution
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honey solution (administered for 15 days)
Trial: 8607570
Drug: Honey (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honey (30 g)
Trial: 15117561
Drug: Sucrose (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (30 g)
Trial: 11961050
Drug: Intravenous ALA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ALA (100 mg)
Trial: 11961050
Drug: Oral ALA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ALA (100 mg)
Trial: 8158698
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy and surgery
Trial: 7891249
Drug: Subgingival chlorexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgingival chlorexidine gel
Trial: 21358290
Drug: Ketorolac 0
RxNorm normalized name: KETOROLAC 0.3/P-EPHR 1% CONC OPH IRR 4ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 0 mg
Trial: 8600742
Drug: Nonaugmented and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonaugmented and ligament augmentation device‐augmented repairs
Trial: 1234497
Drug: ICI 66,082
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 66,082 (200 mg)
Trial: 1234497
Drug: Water (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (control treatment)
Trial: 22708881
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list condition (start cognitive behaviour therapy after 6 months)
Trial: 21163776
Drug: e-therapy program
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: e-therapy program (n = 78)
Trial: 18372693
Drug: Nutrition (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition (daily protein supplement)
Trial: 9526817
Drug: Atorvastatin 5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 5, 20, and 80 mg/day
Trial: 18184901
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 mg
Trial: 29417786
Drug: Knowledge assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge assessment regarding vaccine preventable diseases
Trial: 26238111
Drug: Real acupuncture
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real acupuncture treatment (manual acupuncture plus electroacupuncture)
Trial: 23026870
Drug: Real acupuncture
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real acupuncture treatment
Trial: 23377586
Drug: Dorzolamide/timolol fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide/timolol fixed combination (DTFC)
Trial: 18293187
Drug: Latanoprost/timolol fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost/timolol fixed combination (LTFC)
Trial: 16939542
Drug: Fluvastatin 20-80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 20-80 mg/day
Trial: 11095257
Drug: PTMR with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTMR with a holmium:YAG laser plus continued medical treatment
Trial: 11095257
Drug: Continued medical
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued medical treatment only
Trial: 25495390
Drug: Treated low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treated low thyroid hormone group
Trial: 25495390
Drug: Untreated low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Untreated low thyroid hormone group
Trial: 31659847
Drug: Epidural steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroid injection (ESI)
Trial: 20194711
Drug: Amylin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amylin infusion
Trial: 20194711
Drug: GLP-1 and
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 and amylin infusions
Trial: 7762497
Drug: Long-acting diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting diltiazem 300 mg/day and aspirin 160 mg/day
Trial: 492836
Drug: Amoxicillin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (25 mg/kg)
Trial: 23844756
Drug: Oral combination
RxNorm normalized name: clozapine ORAL COMBINATION PACKAGE (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral combination of diosmin (300 mg/day), C. asiatica (15 mg/day) and Melilotus (160 mg/day)
Trial: 22013932
Drug: Nadroparin (excessive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin (excessive dosage)
Trial: 22013932
Drug: Nadroparin (reduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin (reduced dosage)
Trial: 19211706
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate (TU) 160 mg/day
Trial: 19211706
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate (TU) 80 mg/day
Trial: 3556202
Drug: High-dose budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose budesonide (1600 micrograms/day)
Trial: 9122535
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg
Trial: 8841162
Drug: Medical nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical nutrition therapy from a registered dietitian (one or three visits) in addition to physician or nurse counseling and Grocery Shopping Guide.
Trial: 6662159
Drug: Clonidine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.3 mg p.o.) plus maprotiline (100 mg in 4 divided doses over 22 h)
Trial: 6662159
Drug: Maprotiline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maprotiline (100 mg in 4 divided doses over 22 h)
Trial: 30845034
Drug: Sacroiliac joint
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacroiliac joint arthrodesis with triangular titanium implants
Trial: 26318445
Drug: Ginger (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (2 g/day of ginger powder for 12 weeks)
Trial: 26318445
Drug: Placebo (corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (corn starch as two 1 g tablets for 12 weeks)
Trial: 25257359
Drug: Single-dose 300,000-IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose 300,000-IU intramuscular injection of vitamin D3
Trial: 9680495
Drug: Albuterol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (200 micrograms administered via a Volumatic spacer)
Trial: 9680495
Drug: Prophylactic anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic anti-inflammatory treatment
Trial: 2643863
Drug: Hydrochlorothiazide (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (in combination)
Trial: 29930261
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) injections
Trial: 29930261
Drug: Intranasal (IN)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal (IN) injections
Trial: 29930261
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) injections
Trial: 29203734
Drug: Pioglitazone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15 mg once daily for 6 months)
Trial: 24016492
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus early rhythm control therapy (antiarrhythmic drugs, catheter ablation, and patient-operated ECG device)
Trial: 24016492
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (anticoagulation, therapy of underlying heart disease, and rate control)
Trial: 2409990
Drug: Intravenous ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ethanol (10% v/v; 300 mg kg‐1 body weight for 30 min followed by 3 mg kg‐1 min‐1 for 2 hr)
Trial: 2409990
Drug: Intravenous NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous NaCl (0.15 M)
Trial: 30565779
Drug: Statin initiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin initiation in women with total cholesterol > 240 mg/dL vs < 200 mg/dL during ATP-II period